In a double-blind, randomised controlled phase 3 trial, patients with psoriatic arthritis who have an inadequate response to ≥1 non-biologic disease-modifying anti-rheumatic drug (non-bDMARD) showed improvement in musculoskeletal symptoms, psoriasis, physical function, pain, and fatigue and inhibited radiographic progression when treated with upadacitinib. These improvements were seen by week 2; no new safety signals emerged .
Upadacitinib –an oral, reversible, Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis– is currently under evaluation for treatment of psoriatic arthritis. The SELECT-PsA-1 study, presented by Prof. Iain McInnes (University of Glasgow, Scotland), assessed the efficacy and safety of upadacitinib compared with placebo and adalimumab in patients with psoriatic arthritis and prior inadequate response or intolerance to ≥1 non-bDMARD. Participants ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Opioids becoming more popular with European patients suffering from rheumatic diseases Next Article
Lower venous thromboembolism risk with TNF inhibitors in rheumatoid arthritis »
Table of Contents: EULAR 2020
Osteoporosis and Osteoarthritis
Systemic Sclerosis and Systemic Lupus Erythematosus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.